Cancer Discov. 2016 Jun;6(6):OF9. doi: 10.1158/2159-8290.CD-NB2016-042. Epub 2016 Apr 14.
A new study suggests that insufficient T-cell infiltration may explain why a majority of patients do not respond to immunotherapy. Combining PD-L1 inhibitors with antibody-guided LIGHT, a protein that recruits tumor-infiltrating lymphocytes, increased antitumor response in mice, and may have the potential to improve patient response rates to immunotherapy.
一项新的研究表明，T 细胞浸润不足可能是大多数患者对免疫疗法没有反应的原因。将 PD-L1 抑制剂与抗体引导的 LIGHT（一种募集肿瘤浸润淋巴细胞的蛋白）联合使用，可增加小鼠的抗肿瘤反应，并有潜力提高免疫疗法患者的反应率。
